Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top

Incyte Corporation (INCY) reported second-quarter 2024 adjusted loss of $1.82 per share against the Zacks Consensus Estimate of earnings of 78 cents. The company had recorded earnings of 99 cents per share in the year-ago quarter. Quarter in Detail Opzelura (ruxolitinib) cream generated $121.7 million in sales, which rose 52% year over year and surpassed the Zacks Consensus Estimate of $114 million. The year-over-year rise in sales was driven by patient demand, refills and expansion in payer coverage in bot ...